JOHNS HOPKINS UNIVERSITY
Molecular features promoting sensitivity to LSD1i in castration-resistant prostate cancer
Molecular features promoting sensitivity to LSD1i in castration-resistant prostate cancer is a funding opportunity from JOHNS HOPKINS UNIVERSITY, up to 574881, closing February 28, 2029.
Feb 28, 2029
(943d left)Overview
Prostate cancer (PCa) remains an incurable disease once progression to the metastatic castration-resistant (mCRPC) state occurs; killing 30,000 U.S. men/yr. Unfortunately, each of the FDA-approved agents for mCRPC produces only modest increases in overall survival followed by the emergence of a resistant and more…